Marco Cipolli

Azienda Ospedaliera Universitaria Integrata Verona — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index4.7kcitations165works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Blood disorders and treatments(70), Cystic Fibrosis Research Advances(65), Immunodeficiency and Autoimmune Disorders(45), Pneumocystis jirovecii pneumonia detection and treatment(26), Neonatal Respiratory Health Research(12)

Publications164 total

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center
Pulmonary Therapy·2025Open Access
S68 Long-term effects of elexacaftor/tezacaftor/ivacaftor on clinical outcomes and quality of life among adolescents and adults aged 12+ with cystic fibrosis: Interim results from the TRAJECTORY Study
2025
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR
Frontiers in Pharmacology·2025Open Access
How burdensome is daily respiratory physiotherapy for adults with Cystic Fibrosis undergoing Elexacaftor/Tezacaftor/Ivacaftor (ETI)?
2025
COVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID
Journal of Cystic Fibrosis·2025
Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series
Nature Communications·2025Open Access
Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia
Cell Death Discovery·2025· 2 citedOpen Access
Beyond the bench: Revitalizing ataluren development for rare genetic disorders
Molecular Therapy·2025· 1 cited
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study
Journal of Clinical Medicine·2025· 6 citedOpen Access
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study
Preprints.org·2025· 1 citedOpen Access
Elexacaftor/Tezacaftor/Ivacaftor Efficacy in a Cohort of Italian Patients with CFTR Rare Mutations
International Journal of Translational Medicine·2025· 1 citedOpen Access
Constitutive systemic inflammation in Shwachman-Diamond Syndrome
Molecular Medicine·2025· 3 citedOpen Access
Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome
Journal of Clinical Investigation·2025· 2 citedOpen Access
Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis
Respiratory Research·2025· 2 citedOpen Access
Shwachman-Diamond Syndrome and Diabetes: An Update from the Italian Registry and Review of the Literature
Experimental and Clinical Endocrinology & Diabetes·2025Open Access
Eif6 Dosage Alleviates Activation of the Tp53 Pathway in Sbds-Deficient Cells: A Mechanism for Somatic Genetic Rescue in Shwachman-Diamond Syndrome
Blood·2024
Ataluren Treatment Improves Hematopoietic and Pancreatic Disorders in Patients with Shwachman-Diamond Syndrome
2024Open Access
Real-life effect of elexacaftor/tezacaftor/ivacaftor therapy on microbiological findings in patients with Cystic fibrosis
2024
P339 Maintenance of nutritional parameters improvements over two years of elexacaftor/tezacaftor/ivacaftor (ETI) treatment according to severity of cystic fibrosis (CF) pulmonary disease
Journal of Cystic Fibrosis·2024
Growth Charts for Shwachman–Diamond Syndrome at Ages 0 to 18 Years
Cancers·2024· 4 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Valentino Bezzerri(8), Elena Nicolis(8), Cesare Danesino(6), B.M. Assael(6), Simone Cesaro(6), Carla Colombo(5), Sandra Perobelli(5), Emanuela Maserati(4), Laura Sainati(4), Francesco Pasquali(4), Sonia Volpi(4), Gloria Tridello(4), Giovanna D’Amico(4), Michael W. Konstan(3), Peter R. Durie(3), Michela Francalanci(3), Barbara Messore(3), Antonella Minelli(3), Daniela Longoni(3), Tacjana Pressler(3)